Gene polymorphism of complement factor H in a Turkish patient with membranoproliferative glomerulonephritis type II

Betul Sozeri1, Sevgi Mir, Afig Berdeli

  • 1Department of Pediatric Nephrology, Ege University Faculty of Medicine, Bornova, Izmir, Turkey. betulsozeri@yahoo.com

Insights

Genetic analysis revealed specific complement factor H gene polymorphisms in a patient with Membranoproliferative Glomerulonephritis Type II. These findings support a common mechanism involving complement pathway dysregulation in dense deposit diseases.

Area of Science:

  • Nephrology
  • Genetics
  • Immunology

Background:

  • Membranoproliferative glomerulonephritis (MPGN) involves mesangial/endothelial cell proliferation and capillary wall thickening.
  • MPGN Type II is linked to complement abnormalities, particularly factor H deficiencies caused by CFH gene mutations.

Observation:

  • A 15-year-old boy diagnosed with MPGN II underwent genetic analysis.
  • The patient was found to be heterozygous for polymorphisms in exons 2, 9, and 10 of the complement factor H (CFH) gene.

Findings:

  • The identified CFH gene polymorphisms (c.184G>A, c.1204C>T, c.1419G>A) represent a characteristic genetic profile for MPGN II.
  • This profile indicates the presence of significant risk factors for developing MPGN II.

Implications:

  • The findings support a shared pathogenic mechanism for dense deposit diseases.
  • This mechanism likely involves the dysregulation of the alternative pathway of complement activation.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Complementation Tests00:49

Complementation Tests

A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...